Security Snapshot

ABBOTT LABORATORIES - Common Stock (ABT) Institutional Ownership

CUSIP: 002824100

13F Institutional Holders and Ownership History from Q1 2014 to Q1 2026

Latest Period

Q4 2025

Institutions Reporting

3,236

Shares (Excl. Options)

1,385,918,589

Price

$125.29

Save this security page for your next review

Keep this CUSIP in your watchlists so you can revisit quarter changes from one place.

Type / Class
Equity / Common Stock
Symbol
ABT on NYSE
Shares outstanding
1,742,357,013
Price per share
$100.69
All holders as of 31 Dec 2025
Q4 2025
Total 13F shares
1,385,918,589
Total reported value
$173,534,940,030
% of total 13F portfolios
0.12%
Share change
+30,150,315
Value change
+$3,748,458,758
Number of holders
3,236
Price from insider filings
$100.69
Reported Shares, Excluding Options vs Price
Reported Value, Excluding Options
Total Investors

Quick Takeaways

  • ABT - ABBOTT LABORATORIES - Common Stock is tracked under CUSIP 002824100.
  • 3236 institutions reported positions in Q4 2025.
  • 1 significant owner is listed from Schedule 13D/13G reporting.

What Changed

  • Holder count moved from 3,236 to 1,392 between Q4 2025 and Q1 2026.
  • Reported value moved from $173,534,940,030 to $10,989,041,305.

Why This Matters

  • You can quickly see who holds this security, then open quarter and manager detail pages for full evidence.
  • 13F and Schedule 13D/13G sections are kept together so you can cross-check institutional and beneficial ownership context.

Source Evidence

Source: SEC Form 13F

Latest holder context comes from 3236 institutions filings for Q4 2025.

Open SEC Evidence

Investment Quick Answers

What is CUSIP 002824100?
CUSIP 002824100 identifies ABT - ABBOTT LABORATORIES - Common Stock in SEC 13F datasets.

Where can I see the latest institutional holders?
Review the Q4 2025 holders report and the ownership history table below.

Significant Owners of ABBOTT LABORATORIES - Common Stock (ABT) based on Schedule 13D/G filings

Filer Ownership Change % Holdings Value Net Change Nb Shares Change % Reporting Name Report Period
VANGUARD CAPITAL MANAGEMENT LLC 7.5% $13,416,584,592 130,676,776 Vanguard Capital Management 31 Mar 2026

As of 31 Dec 2025, 3,236 institutional investors reported holding 1,385,918,589 shares of ABBOTT LABORATORIES - Common Stock (ABT). This represents 80% of the company’s total 1,742,357,013 outstanding shares.

Top 25 Institutional Shareholders

The largest institutional shareholders of ABBOTT LABORATORIES - Common Stock (ABT) together control 50% of the company’s outstanding shares — a level of ownership often associated with strong institutional conviction and long‑term capital commitment.

Institution Ownership % Shares Held Share Change % Portfolio % Holdings Value
VANGUARD GROUP INC 10% 175,556,716 +1.4% 0.32% $21,995,500,947
BlackRock, Inc. 8.4% 146,908,768 +3.8% 0.31% $18,406,199,550
STATE STREET CORP 4.6% 79,853,782 +2.1% 0.34% $10,004,880,347
Capital International Investors 3.6% 63,229,445 +2.6% 1.2% $7,922,519,283
Capital Research Global Investors 2.2% 39,169,239 +1% 0.91% $4,907,523,455
GEODE CAPITAL MANAGEMENT, LLC 2.2% 38,407,499 -0.35% 0.3% $4,790,673,850
MORGAN STANLEY 2.1% 36,727,533 -4.9% 0.27% $4,601,592,966
NORGES BANK 1.3% 23,456,714 0.31% $2,938,891,697
WELLINGTON MANAGEMENT GROUP LLP 1.3% 23,434,760 +0.81% 0.51% $2,936,141,081
JPMORGAN CHASE & CO 1.3% 22,193,145 -24% 0.19% $2,780,579,468
BANK OF AMERICA CORP /DE/ 1.1% 19,830,623 -4.7% 0.18% $2,484,578,776
NORTHERN TRUST CORP 1.1% 19,776,651 -3.3% 0.32% $2,477,816,604
T. Rowe Price Investment Management, Inc. 1% 17,887,109 +0.66% 1.4% $2,241,076,000
WELLS FARGO & COMPANY/MN 0.93% 16,285,257 -2.5% 0.4% $2,040,379,928
GOLDMAN SACHS GROUP INC 0.89% 15,496,045 -3.9% 0.28% $1,941,499,478
PRICE T ROWE ASSOCIATES INC /MD/ 0.84% 14,719,154 -6.8% 0.2% $1,844,164,000
MASSACHUSETTS FINANCIAL SERVICES CO /MA/ 0.83% 14,519,346 -3.8% 0.59% $1,819,128,861
STATE FARM MUTUAL AUTOMOBILE INSURANCE CO 0.78% 13,587,118 0% 1.3% $1,702,330,014
Invesco Ltd. 0.77% 13,340,991 -4.4% 0.26% $1,671,492,773
CHARLES SCHWAB INVESTMENT MANAGEMENT INC 0.76% 13,189,528 +0.4% 0.26% $1,652,516,813
AMERIPRISE FINANCIAL INC 0.76% 13,177,262 -2.4% 0.37% $1,644,733,787
Bank of New York Mellon Corp 0.74% 12,926,170 +2% 0.29% $1,619,519,827
Legal & General Group Plc 0.72% 12,620,564 -2.2% 0.35% $1,581,230,466
ALLIANCEBERNSTEIN L.P. 0.71% 12,451,937 +125% 0.49% $1,560,103,187
Nuveen, LLC 0.68% 11,794,805 +1.2% 0.39% $1,477,771,078

Institutional Holders of ABBOTT LABORATORIES - Common Stock (ABT) across Reporting Periods

Period Reported Shares, Excl. Options Value, Excl. Options Value Change Price (Median) Investors
2026 Q1 107,167,958 $10,989,041,305 +$151,970,780 $102.67 1,392
2025 Q4 1,385,918,589 $173,534,940,030 +$3,748,458,758 $125.29 3,236
2025 Q3 1,354,439,160 $181,328,416,526 -$2,729,817,185 $133.94 3,151
2025 Q2 1,373,457,328 $186,724,601,473 +$3,689,370,235 $136.01 3,151
2025 Q1 1,348,790,206 $178,801,336,976 +$458,110,755 $132.65 3,135
2024 Q4 1,346,298,072 $152,329,939,683 +$4,602,128,635 $113.11 3,033
2024 Q3 1,300,355,763 $148,247,878,720 -$1,716,781,783 $114.01 2,874
2024 Q2 1,316,417,932 $136,784,452,486 +$2,136,359,246 $103.91 2,843
2024 Q1 1,302,852,431 $147,952,633,332 -$186,373,857 $113.66 2,884
2023 Q4 1,304,983,629 $143,636,729,289 +$702,840,266 $110.07 2,868
2023 Q3 1,296,567,862 $125,616,929,945 -$511,707,264 $96.85 2,664
2023 Q2 1,300,801,326 $141,636,058,128 -$238,716,500 $109.02 2,714
2023 Q1 1,303,370,319 $131,997,378,367 +$456,259,624 $101.26 2,685
2022 Q4 1,295,641,185 $142,311,403,748 -$88,117,082 $109.79 2,741
2022 Q3 1,295,186,205 $125,419,250,679 +$340,947,519 $96.76 2,596
2022 Q2 1,292,982,597 $140,507,109,818 +$1,291,772,556 $108.65 2,676
2022 Q1 1,290,037,320 $152,773,075,671 -$1,347,741,981 $118.36 2,744
2021 Q4 1,298,568,047 $182,637,730,877 -$1,037,752,022 $140.74 2,792
2021 Q3 1,304,329,872 $154,105,545,758 -$489,063,797 $118.13 2,518
2021 Q2 1,308,302,318 $151,667,725,087 -$1,382,462,665 $115.93 2,492
2021 Q1 1,318,091,663 $157,927,510,389 +$1,631,328,365 $119.84 2,510
2020 Q4 1,307,462,033 $143,116,956,354 +$331,022,292 $109.49 2,473
2020 Q3 1,306,014,624 $142,022,460,179 -$6,984,888 $108.83 2,293
2020 Q2 1,304,304,663 $119,298,426,006 -$1,426,498,089 $91.43 2,237
2020 Q1 1,320,881,349 $104,282,756,007 -$474,548,989 $78.91 2,118
2019 Q4 1,324,729,656 $115,053,827,077 +$582,610,959 $86.86 2,181
2019 Q3 1,320,917,464 $110,486,349,698 -$172,855,428 $83.67 2,020
2019 Q2 1,320,235,491 $111,014,490,159 +$1,880,435,078 $84.10 2,003
2019 Q1 1,313,334,925 $104,961,645,831 -$610,840,495 $79.94 1,992
2018 Q4 1,321,863,765 $95,580,892,549 +$1,894,141,670 $72.33 1,962
2018 Q3 1,293,120,470 $94,835,420,854 +$2,995,171,785 $73.36 1,856
2018 Q2 1,254,589,153 $76,508,542,840 -$964,494,217 $60.99 1,801
2018 Q1 1,274,488,709 $76,351,995,921 +$368,748,979 $59.92 1,796
2017 Q4 1,267,615,293 $72,341,691,509 -$422,486,325 $57.07 1,746
2017 Q3 1,273,140,330 $67,943,393,768 +$614,368,368 $53.36 1,591
2017 Q2 1,263,195,777 $61,401,759,006 +$808,713,177 $48.61 1,569
2017 Q1 1,251,255,326 $55,565,381,743 +$10,527,320,695 $44.41 1,585
2016 Q4 1,106,373,205 $42,516,265,016 +$407,904,281 $38.41 1,514
2016 Q3 1,091,633,492 $46,138,705,256 +$1,153,981,971 $42.29 1,484
2016 Q2 1,067,624,130 $41,983,022,819 +$1,701,516,839 $39.31 1,467
2016 Q1 1,022,822,267 $42,778,202,179 -$173,321,678 $41.83 1,457
2015 Q4 1,027,740,304 $46,154,356,293 -$497,206,316 $44.91 1,498
2015 Q3 1,037,112,499 $41,717,834,562 +$274,539,953 $40.22 1,452
2015 Q2 1,033,961,965 $50,752,165,358 +$294,425,750 $49.08 1,478
2015 Q1 1,028,648,801 $47,650,459,140 -$625,423,849 $46.33 1,463
2014 Q4 1,043,914,792 $46,996,777,711 +$448,236,438 $45.02 1,472
2014 Q3 1,028,753,494 $42,786,861,710 +$362,567,670 $41.59 1,388
2014 Q2 1,019,994,541 $41,715,229,215 +$96,928,621 $40.90 1,377
2014 Q1 1,020,830,174 $39,305,027,565 -$1,235,422,500 $38.51 1,367
We use cookies and similar technologies to provide certain features, enhance the user experience and, if you allow them, measure engagement and deliver advertising. Analytics and marketing storage stay off until you grant consent. By clicking on "Agree and continue", you declare your consent to the use of the selected optional cookies. Here you can make detailed settings or revoke your consent (in part if necessary) with effect for the future. For further information, please refer to our Privacy Policy .